DeuterOncology Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

DeuterOncology General Information

Description

Developer of MET inhibitors intended to optimize oncology treatments and outcomes. The company's lead compound is a dual MET and RAS pathway inhibitor under pre-clinical investigation as a targeted therapy for lung cancer, as well as potential broader oncology applications when used in combination with other SOC and targeted agents, enabling medical professionals to treat cancer patients effectively.

Contact Information

Website
www.deuteroncology.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Afinis Business Centre
  • Clos Chanmurly 13
  • 4000 Liege
  • Belgium
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Pathos AI
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Afinis Business Centre
  • Clos Chanmurly 13
  • 4000 Liege
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DeuterOncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 06-May-2026 Completed Clinical Trials - Phase 2
3. Grant 07-Apr-2023 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 19-Jan-2023 $6.04M $7.25M Completed Clinical Trials - Phase 2
1. Early Stage VC 24-Feb-2021 $1.21M $1.21M Completed Pre-Clinical Trials
To view DeuterOncology’s complete valuation and funding history, request access »

DeuterOncology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A Shares
To view DeuterOncology’s complete cap table history, request access »

DeuterOncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DeuterOncology Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Newton BioCapital Venture Capital Minority
Noshaq Venture Capital Minority
ORSA FUND Venture Capital Minority
radiomics.bio VC-Backed Company
To view DeuterOncology’s complete investors history, request access »

Ready to get started?

Request a free trial

DeuterOncology FAQs

  • When was DeuterOncology founded?

    DeuterOncology was founded in 2020.

  • Where is DeuterOncology headquartered?

    DeuterOncology is headquartered in Liege, Belgium.

  • What is the size of DeuterOncology?

    DeuterOncology has 3 total employees.

  • What industry is DeuterOncology in?

    DeuterOncology’s primary industry is Drug Discovery.

  • Is DeuterOncology a private or public company?

    DeuterOncology is a Private company.

  • What is DeuterOncology’s current revenue?

    The current revenue for DeuterOncology is .

  • How much funding has DeuterOncology raised over time?

    DeuterOncology has raised $7.25M.

  • Who are DeuterOncology’s investors?

    Newton BioCapital, Noshaq, ORSA FUND, and radiomics.bio have invested in DeuterOncology.

  • When was DeuterOncology acquired?

    DeuterOncology was acquired on 06-May-2026.

  • Who acquired DeuterOncology?

    DeuterOncology was acquired by Pathos AI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process